Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
Citations Over TimeTop 10% of 2017 papers
Abstract
Melanoma treatment has been revolutionized by antibody-based immunotherapies. IFNγ secretion by CD8+ T cells is critical for therapy efficacy having anti-proliferative and pro-apoptotic effects on tumour cells. Our study demonstrates a genetic evolution of IFNγ resistance in different melanoma patient models. Chromosomal alterations and subsequent inactivating mutations in genes of the IFNγ signalling cascade, most often JAK1 or JAK2, protect melanoma cells from anti-tumour IFNγ activity. JAK1/2 mutants further evolve into T-cell-resistant HLA class I-negative lesions with genes involved in antigen presentation silenced and no longer inducible by IFNγ. Allelic JAK1/2 losses predisposing to IFNγ resistance development are frequent in melanoma. Subclones harbouring inactivating mutations emerge under various immunotherapies but are also detectable in pre-treatment biopsies. Our data demonstrate that JAK1/2 deficiency protects melanoma from anti-tumour IFNγ activity and results in T-cell-resistant HLA class I-negative lesions. Screening for mechanisms of IFNγ resistance should be considered in therapeutic decision-making.
Related Papers
- → The Melanoma Epidemic: More Apparent Than Real?(1997)97 cited
- → Treatment of Malignant Melanoma by Selective Thermal Neutron Capture Therapy Using Melanoma-Seeking Compound(1989)36 cited
- → Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients(1978)41 cited
- → Inhibition of leukocyte migration in agarose by KC1 extracts of a human melanoma cell line grown in serum‐free medium(1975)16 cited
- → Preoperative diagnosis of malignant melanoma using the touch-fluorescence method(1993)8 cited